Louis W. Sullivan - 24 Jul 2025 Form 4 Insider Report for UNITED THERAPEUTICS Corp (UTHR)

Reporting relationship: Director
Issuer ticker: UTHR
Reported as of: 24 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Jul 2025, 06:21:46 UTC
Prior SEC filing: 02 May 2025
Next SEC filing: 23 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ John S. Hess, Jr. under Power of Attorney

Key filing fact

Louis W. Sullivan filed Form 4 for UNITED THERAPEUTICS Corp (UTHR) on 28 Jul 2025.

Key facts

This page summarizes Louis W. Sullivan's Form 4 filing for UNITED THERAPEUTICS Corp (UTHR).
4 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 28 Jul 2025, 06:21.

Change

Previous filing in this sequence was filed on 02 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001193522 Primary reporting owner

SULLIVAN LOUIS W

Relationship: Director
Address: C/O UNITED THERAPEUTICS CORPORATION, 1000 SPRING STREET, SILVER SPRING
Signature: /s/ John S. Hess, Jr. under Power of Attorney
Signature date: 25 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

UTHR transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +590
Change %
Price: $0.000000
Shares after: 590
Date: 25 Jul 2025
Ownership: by Trust
Footnotes: F1, F2

UTHR holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 3,200
Date: 24 Jul 2025
Ownership: by Trust
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

UTHR transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value: $0
Shares: -590
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 25 Jul 2025
Ownership: by Trust
Underlying class: Common Stock
Underlying amount: 590
Exercise price: $0.000000
Footnotes: F1, F3, F4

UTHR transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +650
Change %
Price: $0.000000
Shares after: 650
Date: 24 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 650
Exercise price: $0.000000
Footnotes: F3, F5, F6

UTHR transaction Derivative

Stock Options

Award

Transaction value: $0
Shares: +1,830
Change %
Price: $0.000000
Shares after: 1,830
Date: 24 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,830
Exercise price: $306.41
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Shares received upon vesting of restricted stock units on July 25, 2025. Restricted stock units converted on a one-for-one basis into shares of common stock.

Footnote F2

These common stock shares are held indirectly by a trust over which the reporting person has sole investment power and sole voting power.

Footnote F3

Not applicable as restricted stock units do not have an expiration date.

Footnote F4

These restricted stock units were held indirectly by a trust over which the reporting person has sole investment power and sole voting power.

Footnote F5

Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

Footnote F6

Annual non-employee director award.